Biotika As logo

1BSL01AE - Biotika As Share Price

€45 0.0  0.0%

Last Trade - 06/10/16

Sector
Healthcare
Size
Micro Cap
Market Cap £22.9m
Enterprise Value £18.3m
Revenue £1.66m
Position in Universe 373rd / 790
Bullish
Bearish
Unlock 1BSL01AE Revenue
Momentum
Relative Strength (%)
1m +21.8%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -2.56%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
1.59 1.89 1.92 1.74 1.38 2.01 +4.8%
+63.1 +60.0 -78.7 -94.5 +2,310 +63.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Biotikaa.s. revenues increased 46% to EUR2M. Net income increased79% to EUR2M. Revenues reflect Pharmacy segment increasefrom EUR54K to EUR521K, Services segment increase of 12% toEUR1.5M, United States segment increase from EUR319K toEUR1.8M, France segment increase from EUR275K to EUR731K.Net income benefited from Services Cost decrease of 46% toEUR1.3M (expense), B.V.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

1BSL01AE Revenue Unlock 1BSL01AE Revenue

Net Income

1BSL01AE Net Income Unlock 1BSL01AE Revenue

Normalised EPS

1BSL01AE Normalised EPS Unlock 1BSL01AE Revenue

PE Ratio Range

1BSL01AE PE Ratio Range Unlock 1BSL01AE Revenue

Dividend Yield Range

1BSL01AE Dividend Yield Range Unlock 1BSL01AE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
1BSL01AE EPS Forecasts Unlock 1BSL01AE Revenue
Profile Summary

Biotika as is a Slovakia-based joint stock company that specializes in biotechnology and production of pharmaceutical. The Company's activities are grouped into three main areas: biotechnological production of the substances of penicillin, chlorotetracycline and dextrans; production of final drug-forms for both human and veterinary use, including: penicillin and cephalosporin preparations, hormonal preparations, vitamin preparations; as well as production of premixes containing nutrition additives and medicated nutritive preparations. As of December 31, 2011, the Company operated two wholly owned subsidiaries, COV as Slovenska Lupca and Biotkika KLF as Slovenska Lupca.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated May 1, 1992
Public Since November 19, 1993
No. of Shareholders: n/a
No. of Employees: 279
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Bratislava Stock Exchange
Shares in Issue 700,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
1BSL01AE Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 1BSL01AE
Upcoming Events for 1BSL01AE
Frequently Asked Questions for Biotika as
What is the Biotika as share price?

As of 06/10/16, shares in Biotika as are trading at €45, giving the company a market capitalisation of £22.9m. This share price information is delayed by 15 minutes.

How has the Biotika as share price performed this year?

Shares in Biotika as are currently trading at €45 and the price has moved by 18.75% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biotika as price has moved by 7.22% over the past year.

What are the analyst and broker recommendations for Biotika as?

There are no analysts currently covering Biotika as.

When will Biotika as next release its financial results?

Biotika as is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Biotika as dividend yield?

The Biotika as dividend yield is 6.05% based on the trailing twelve month period.

Does Biotika as pay a dividend?

Last year, Biotika as paid a total dividend of 2.3, and it currently has a trailing dividend yield of 6.05%. Looking ahead, Biotika as has not announced an ex-dividend date yet.

When does Biotika as next pay dividends?

Biotika as has yet to annouce their ex-dividend date. The historic dividend yield on Biotika as shares is currently 6.05%.

How do I buy Biotika as shares?

To buy shares in Biotika as you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biotika as?

Shares in Biotika as are currently trading at €45, giving the company a market capitalisation of £22.9m.

Where are Biotika as shares listed? Where are Biotika as shares listed?

Here are the trading details for Biotika as:

Country of listing: Slovakia
Exchange: BRA
Ticker Symbol: 1BSL01AE
What kind of share is Biotika as?

Based on an overall assessment of its quality, value and momentum, Biotika as is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biotika as share price forecast 2021?

We were not able to load any forecast data for Biotika as.

How can I tell whether the Biotika as share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotika as. Over the past six months, the relative strength of its shares against the market has been 13.85%. At the current price of €45, shares in Biotika as are trading at 22.53% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biotika as PE Ratio?

The Biotika as PE ratio based on its reported earnings over the past 12 months is 10.17. The shares are currently trading at €45.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Biotika as?

Biotika as's management team is headed by:

Petrus Winkelman - VSU
Peter Draskovic - SUB
Milan Mocik - FID
Slavomir Geleta - OTH
Maria Jakubcova - OTH
Emil Drlicka - CMG
Maria Kincesova - CSU
Viera Druskova - OTH
Dagmar Vargova - SUB
Jozef Trangos - SUB
Jozef Debnarik - SUB
Denisa Chramcova - GCN
Andrea Lilkova - DSL
Jana Eervenakova - OTH
Who are the major shareholders of Biotika as?

Here are the top five shareholders of Biotika as based on the size of their shareholding:

BIO S.L., a.s Corporation
Percentage owned: 30.2% (171k shares)
Escort(Ivan Varga) Individual Investor
Percentage owned: 20.3% (115k shares)
GV Pharma AS Corporation
Percentage owned: 17% (96.0k shares)
London Pharma & Chemicals Group Ltd Corporation
Percentage owned: 9.9% (55.9k shares)
Similar to 1BSL01AE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.